Post hoc subgroup analysis of DESTINY-Breast06 (N=866, HR-positive HER2-low/-ultralow metastatic breast cancer): trastuzumab deruxtecan improved median PFS vs chemotherapy regardless of time to progression on prior ET+CDK4/6i (eg <6 months: 14.0 vs 6.5 months) or disease burden.
Secondary analysisn = 866
Curigliano et al. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease